What role can function magnetic resonance imaging (fMRI) have in guiding therapy for depression?

References

• McIntyre RS, Alsuwaidan M, Baune BT, et al. Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023;22(3):394–412. doi: 10.1002/wps.21120
   PubMed Web of Science ®Google Scholar
• Kotoula V, Evans JW, Punturieri C, et al. Functional MRI markers for treatment-resistant depression: insights and challenges. Prog Brain Res. 2023;278:117–148. doi: 10.1016/bs.pbr.2023.04.001
   PubMedGoogle Scholar
• Stoyanov DS, Stieglitz R-D, Lenz C, et al. The translational validation as novel approach to intergration of neuroscience and psychiatry. In: Stoyanov D, Stiegliltz RD, editors. New developments in clinical psychology research. NY: Nova Science Publishers: 2015. p. 196–208.
   Google Scholar
• Stoyanov DS, Borgwardt SJ, Varga S. Translational validity across neuroscience and psychiatry. Oxford: Oxford University Press; 2014; p. 128–145.
   Google Scholar
• Di Nicola V, Stoyanov D, Di Nicola V et al. Psychiatric nosology revisited: at the crossroads of psychology and medicine. Psychiatr Crisis: At The Crossroads Social Sci Humanit Neurosci. Cham: Springer Nature; 2021. p. 31–41.
   Google Scholar
• Möller HJ, Von Zerssen D. Self-rating procedures in the evaluation of antidepressants: review of the literature and results of our studies. Psychopathology. 1995;28(6):291–306. doi: 10.1159/000284941
   PubMed Web of Science ®Google Scholar
• Stoyanov D, Machamer P, Schaffner KF. In quest for scientific psychiatry: toward bridging the explanatory gap. Philosophy, Psychiatry, Psychol. 2013;20(3):261–273. doi: 10.1353/ppp.2013.0041
   Google Scholar
• Aryutova K, Stoyanov D. Pharmaco-magnetic resonance as a tool for monitoring the medication-related effects in the brain may provide potential biomarkers for psychotic disorders. Int J Mol Sci. 2021;22(17):9309.
   PubMed Web of Science ®Google Scholar
• Aryutova K, Stoyanov DS, Kandilarova S, et al. Clinical use of neurophysiological biomarkers and self-assessment scales to predict and monitor treatment response for psychotic and affective disorders. Curr Pharm Des. 2021;27(39):4039–4048. doi: 10.2174/1381612827666210406151447
   PubMed Web of Science ®Google Scholar
• Kandilarova S, Stoyanov D*, Aryutova K, Paunova R, Mantarkov M, Mitrev I, Todeva-Radneva A and Specht K. Effective connectivity between the orbitofrontal cortex and the precuneus differentiates major psychiatric disorders: results from a transdiagnostic spectral DCM study. CNS Neurol Disord - Drug Targets. 2023;22 2(2):180–190. doi: 10.2174/1871527320666210917142815
   PubMed Web of Science ®Google Scholar
• Stoyanov D, Khorev V, Paunova R, et al. Resting-state functional connectivity impairment in patients with Major Depressive Episode. Int J Environ Res Public Health. 2022;19(21):14045. doi: 10.3390/ijerph192114045
   PubMed Web of Science ®Google Scholar
• Li J, Chen J, Kong W, et al. Abnormal core functional connectivity on the pathology of MDD and antidepressant treatment: a systematic review. J Affective Disorders. 2022;296:622–634. doi: 10.1016/j.jad.2021.09.074
   PubMed Web of Science ®Google Scholar
• Dichter GS, Gibbs D, Smoski MJ. A systematic review of relations between resting-state functional-MRI and treatment response in major depressive disorder. J Affective Disorders. 2015;172(2015):8–17.
   PubMedGoogle Scholar
• Morgieve M, Gaudeau C, Clair AH, et al. P-814-Longitudinal fMRI assessment of cognitive and behavioral therapy for obsessive compulsive disorder: are there neurobiological markers of response to treatment? Eur Psychiatry. 2012;27(S1):1–1. doi: 10.1016/S0924-9338(12)74981-7
   PubMedGoogle Scholar
• Stoyanov D. Perspectives before incremental trans-disciplinary cross-validation of clinical self-evaluation tools and functional MRI in psychiatry: 10 years later. Front Psychiatry. 2022;13:999680. doi: 10.3389/fpsyt.2022.999680
   PubMed Web of Science ®Google Scholar
• Stoyanov D, Khorev V, Paunova R, et al. Group independent components underpin responses to items from a depression scale. Acta Neuropsychiatr. 2024;36(1):9–16. doi: 10.1017/neu.2023.22
   PubMed Web of Science ®Google Scholar
• Stoyanov D, Paunova R, Dichev J, et al. Functional magnetic resonance imaging study of group independent components underpinning item responses to paranoid-depressive scale. World J Clin Cases. 2023 Dec 26;11(36):8458–8474. doi: 10.12998/wjcc.v11.i36.8458
   PubMed Web of Science ®Google Scholar
• Stoyanov D, Kandilarova S, Paunova R, et al. Cross-validation of functional MRI and paranoid-depressive scale: results from multivariate analysis. Front Psychiatry. 2019;10:869. doi: 10.3389/fpsyt.2019.00869
   PubMed Web of Science ®Google Scholar
• Paunova R, Kandilarova S, Todeva-Radneva A, et al. Application of mass multivariate analysis on neuroimaging data sets for precision diagnostics of depression. Diagnostics. 2022;12(2):469. doi: 10.3390/diagnostics12020469
   Web of Science ®Google Scholar
• Marek S, Tervo-Clemmens B, Calabro FJ, et al. Reproducible brain-wide association studies require thousands of individuals. Nature. 2022;603(7902):654–660. doi: 10.1038/s41586-022-04492-9
   PubMed Web of Science ®Google Scholar
• Arnone D. Functional MRI findings, pharmacological treatment in major depression and clinical response. Prog Neuro Psychopharmacol Biol Psychiatry. 2019;91(2019):28–37. doi: 10.1016/j.pnpbp.2018.08.004
   PubMedGoogle Scholar